Efficacy and clinical outcome of chemotherapy and endocrine therapy as first-line treatment in patients with hormone receptor-positive HER2-negative metastatic breast cancer | Chinese Medical Journal
Update on systemic treatment for newly diagnosed inflammatory breast cancer - ScienceDirect
Navigating HR+/HER2- Early Breast Cancer Treatment Strategies - Cancer Therapy Advisor
Chemotherapy With Endocrine Therapy Shows Clinical Benefit With Improved Survival in Breast Cancer
BREAST CANCER - Daily Reporter
PDF) Real-World Evaluation of Disease Progression After CDK 4/6 Inhibitor Therapy in Patients With Hormone Receptor-Positive Metastatic Breast Cancer
Endocrine Therapeutic Strategies for Patients with Hormone Receptor-positive Advanced Breast Cancer | touchONCOLOGY
Current Oncology | Free Full-Text | Capecitabine Plus Aromatase Inhibitor as First Line Therapy for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer
The Evolving Role of Angiogenesis Inhibition in Treatment of Breast Cancer
Switch maintenance endocrine therapy plus bevacizumab after bevacizumab plus paclitaxel in advanced or metastatic oestrogen receptor-positive, HER2-negative breast cancer (BOOSTER): a randomised, open-label, phase 2 trial - The Lancet Oncology
Adjuvant chemotherapy plus endocrine therapy fails to increase OS in breast cancer subset
Neoadjuvant Endocrine Therapy as an Alternative to Neoadjuvant Chemotherapy Among Hormone Receptor-Positive Breast Cancer Patients: Pathologic and Surgical Outcomes | Annals of Surgical Oncology
Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer | NEJM
Status of adjuvant endocrine therapy for breast cancer | Breast Cancer Research | Full Text
Type of adjuvant endocrine therapy and disease-free survival in patients with early HR-positive/HER2-positive BC: analysis from the phase III randomized ShortHER trial | npj Breast Cancer
Current Oncology | Free Full-Text | Capecitabine Plus Aromatase Inhibitor as First Line Therapy for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer
Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study - ScienceDirect
Impact of deviation from guideline recommended treatment on breast cancer survival in Asia | Scientific Reports
Frontiers | Comparison of endocrine therapy and chemotherapy as different systemic treatment modes for metastatic luminal HER2-negative breast cancer patients —A retrospective study
Cancer treatment and survivorship statistics, 2022 - Miller - 2022 - CA: A Cancer Journal for Clinicians - Wiley Online Library
Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy | Breast Cancer Research | Full Text
CDK4/6 inhibitors plus endocrine therapy improve overall survival in advanced HR+/HER2− breast cancer: A meta‐analysis of randomized controlled trials - Wang - 2020 - The Breast Journal - Wiley Online Library
Adjuvant Chemotherapy Improves Prostate Cancer Survival - NCI
Frontiers | Different treatment regimens in breast cancer visceral crisis: A retrospective cohort study
Using population-based data to evaluate the impact of adherence to endocrine therapy on survival in breast cancer through the web-application BreCanSurvPred | Scientific Reports
Breast cancer recurrence: factors impacting occurrence and survival | Irish Journal of Medical Science (1971 -)
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer | NEJM
